Pennant PNTG
- Market cap
- $1.5B
- PE
- 46.5×
- 6y median 47.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.3×
- EV/EBIT
- 25.1×
- Revenue, 12 months
- $1.1B
- +38% on a year ago
- Net margin
- 2.9%
- Free cash flow yield
- 2.4%
Pennant trades at 46.5× trailing earnings, near its ten-year median. Revenue was $1.1B over the last twelve months, up 38% on a year earlier with a 3% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $140.2M+19% | $146M+17% | $156.9M+24% | $168.7M+28% | $180.7M+29% | $188.9M+29% | $209.8M+34% | $219.5M+30% | $229M+27% | $289.3M+53% | $285.4M+36% | $298M+36% | |
| Cost of revenue | $112.4M+19% | $116.9M+18% | $126M+23% | $135.3M+27% | $144.5M+29% | $152.7M+31% | $168.7M+34% | $177.3M+31% | $185.4M+28% | $237.1M+55% | $232.7M+38% | $242.6M+37% |
| Gross profit | $27.8M+18% | $29M+13% | $30.9M+30% | $33.4M+28% | $36.2M+30% | $36.2M+25% | $41.1M+33% | $42.2M+26% | $43.6M+20% | $52.3M+44% | $52.7M+28% | $55.3M+31% |
| SG&A | $9.4M+60% | $9.8M+17% | $11.4M+31% | $11.9M+35% | $13M+38% | $13.9M+42% | $14.8M+30% | $17.6M+48% | $19.3M+48% | $19.3M+39% | $19.7M+33% | $21.6M+23% |
| $7.1M−1% | $7.6M+19% | $8.5M+99% | $9.6M+53% | $10.8M+53% | $9.2M+22% | $12.7M+48% | $11.5M+21% | $10.2M−5% | $17.5M+89% | $17.3M+37% | $17.2M+49% | |
| Interest expense | $1.5M+41% | $1.6M+20% | $1.8M+28% | $1.6M+12% | $2.9M+93% | $650K−59% | $1.2M−33% | $1.2M−26% | $1M−65% | $3.3M+401% | $3.1M+155% | $3.3M+178% |
| Pre-tax income | $5.5M−9% | $6.3M+24% | $6.8M+135% | $7.9M+64% | $8M+45% | $8.6M+36% | $11.4M+67% | $10.6M+33% | $9.4M+17% | $14.3M+66% | $14.1M+24% | $14.8M+40% |
| $1.1M−1% | $1.8M+26% | $1.8M+94% | $1.8M−4% | $1.4M+27% | $2.1M+16% | $2.9M+62% | $2.6M+41% | $2.5M+86% | $3.9M+88% | $3.8M+33% | $3.9M+52% | |
| Net income | $4.4M−9% | $4.3M+25% | $4.9M+165% | $5.7M+103% | $6.2M+42% | $5.8M+32% | $7.8M+59% | $7.1M+25% | $6.1M−2% | $8.6M+50% | $8.5M+10% | $9.1M+28% |
| $0.15−6% | $0.14+17% | $0.16+167% | $0.18+100% | $0.20+33% | $0.16+14% | $0.22+38% | $0.20+11% | $0.17−15% | $0.24+50% | $0.24+9% | $0.25+25% | |
| 30.2M+0% | 30.2M+1% | 30.4M+1% | 30.8M+2% | 31.4M+4% | 35.4M+17% | 35.2M+16% | 35.4M+15% | 35.3M+13% | 35.4M+0% | 35.8M+2% | 36M+2% |
Gross profit: 32 periods, Q3 FY18 to Q2 FY26: not printed by the filing, worked out from its own lines.
Operating income: Q3 FY18 and Q3 FY19: not printed by the filing, worked out from its own lines.
EPS, diluted: 8 periods, Q4 FY18 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY18 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. Q4 FY19 and Q4 FY21: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Pennant's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| PNTGPennant | $1.5B | 46.5× | 47.0× | 1.3× | +38% | 2.9% | |
| USPHU S Physical Therapy | $1.3B | 101× | 42.1× | 1.6× | +11% | 4.0% | |
| ARDTArdent Health | $1.7B | 22.3× | 8.5× | 0.3× | +3% | 1.2% | |
| HCSGHealthcare Services | $1.7B | 14.7× | 26.1× | 0.9× | +4% | 6.6% | |
| OMDAOmada Health | $1.2B | 316× | 341× | 3.7× | +48% | 1.4% | |
| PGNYProgyny | $2.2B | 31.5× | 55.1× | 1.7× | +6% | 6.0% | |
| ADUSAddus HomeCare | $2.3B | 21.4× | 32.4× | 1.5× | +16% | 7.1% | |
| MDPediatrix Medical | $2.4B | 14.0× | 13.4× | 1.2× | +1% | 9.0% | |
| PRVAPrivia Health | $2.9B | 107× | 158× | 1.2× | +24% | 1.2% | |
| AVAHAveanna Healthcare | $2.9B | 10.9× | 21.8× | 1.1× | +20% | 10.6% | |
| NHCNational Healthcare | $3.7B | 26.5× | 21.4× | 2.4× | +7% | 9.0% | |
| Peer median | $2.2B | 24.4× | 29.2× | 1.4× | +9% | 6.3% |
More on Pennant
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .